Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature.
Phil-Robin TepasseWali HafeziMathias LutzJoachim KühnChristian WilmsRainer WiewrodtJan SackarndMartin KellerHartmut H SchmidtRichard VollenbergPublished in: British journal of haematology (2020)
SARS-CoV-2 infection can cause severe pneumonia (COVID-19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS-CoV-2 viraemia with fatal outcome in patients after rituximab therapy.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- end stage renal disease
- diffuse large b cell lymphoma
- coronavirus disease
- ejection fraction
- newly diagnosed
- early onset
- chronic kidney disease
- prognostic factors
- stem cells
- hodgkin lymphoma
- peritoneal dialysis
- intensive care unit
- patient reported outcomes
- smoking cessation
- replacement therapy